Analysis: Merck's statins turn up more muscle side effects than their rivals

Statins have long come with safety worries, but a new analysis shows that Merck & Co.'s ($MRK) products may carry more than their brethren. Pacing side effects data, Advera Health Analytics found that muscle-related side effects--which are commonly linked to the drugs--show up more often in the New Jersey giant's Zocor, Mevacor and Vytorin than in drugs in the rest of the class. More from FiercePharma